Currently, 48% of people diagnosed with human immunodeficiency virus (HIV) in the United States are age ≥ 50, and as the HIV-infected population ages it becomes increasingly important to identify comorbidities and consider them when optimizing treatment decisions, as they can involve risk of cardiovascular complications, renal disease, osteoporosis, and bone fracture.
In this CME Outfitters BriefCase, expert faculty will present a patient case focusing on the impact of comorbidities and how to individualize treatment regimens for aging patients with HIV, based on their specific needs and comorbidities.
At the end of this CME/CE activity, participants should be able to individualize treatment regimens for aging patients with HIV, based on their specific needs and comorbidities.
The following learning objectives pertain only to those requesting CNE or CPE credit: Describe individualized treatment regimens for aging patients with HIV, based on their specific needs and comorbidities.
Supported by educational grants from Gilead Sciences, Inc., Merck & Co., Inc., and ViiV Healthcare. The supporters were not involved in the development of content or the selection of faculty for this educational activity.
Infectious disease specialists, primary care physicians, PAs, nurse practitioners, nurses, pharmacists.
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Wohl reports that he receives research support and grants from Gilead Sciences, Inc.; Merck & Co., Inc.; and ViiV Healthcare. He is on the advisory committee for Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; and ViiV Healthcare.
Jeffrey Helfand, DO (peer reviewer) has no disclosures to report.
Mae Ochoa, RPh (peer reviewer) has no disclosures to report.
Susan Perry (planning committee) has no disclosures to report.
Jan Perez (planning committee) has no disclosures to report.
Sharon Tordoff (planning committee) has no disclosures to report.
Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
NOTE: Pharmacist CE Universal Activity Number, Enduring: 0376-0000-20-149-H01-P.
Call us at 877.CME.PROS (877.263.7767).